Sen. Dianne Feinstein reduced biotech exposure worth up to $6M shortly before pandemic volatility hit the sector. As a member of the Senate Health Committee, her risk management timing demonstrated deep sector expertise.

Analysts Involved

  • Dianne Feinstein

Regulatory Outcome

DOJ investigation closed. No charges.